Calliditas Therapeutics

Mindre end 1K følgere

Alle

Selskabspræsentationer

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse30.9.2024, 12.30

Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics

Selskabsmeddelelse16.9.2024, 13.30

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

Calliditas Therapeutics

Selskabsmeddelelse3.9.2024, 10.15

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Calliditas Therapeutics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse3.9.2024, 10.00

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics

Pressemeddelelse15.8.2024, 09.45

Redeye: Calliditas Update - The Final Countdown

Calliditas Therapeutics

Calliditas Therapeutics, Audiocast with teleconference, Q2'24

Videopræsentation13.8.2024, 12.30

Calliditas Therapeutics, Audiocast with teleconference, Q2'24

Calliditas Therapeutics

Selskabsmeddelelse13.8.2024, 05.00

Calliditas Therapeutics: Calliditas Interim Report January to June 2024

Calliditas Therapeutics

Pressemeddelelse5.8.2024, 05.00

Calliditas Therapeutics: Invitation to the presentation of Calliditas's interim report January - June 2024

Calliditas Therapeutics

Selskabsmeddelelse31.7.2024, 12.00

Number of shares and votes in Calliditas Therapeutics

Calliditas Therapeutics

Pressemeddelelse26.7.2024, 15.00

Calliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

Calliditas Therapeutics

Selskabsmeddelelse26.7.2024, 06.00

Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

Calliditas Therapeutics

Pressemeddelelse4.7.2024, 06.30

Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan

Calliditas Therapeutics

Pressemeddelelse18.6.2024, 10.15

Calliditas Therapeutics: Calliditas provides setanaxib patent update

Calliditas Therapeutics

Selskabsmeddelelse17.6.2024, 15.30

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics

Selskabsmeddelelse30.5.2024, 18.00

Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy

Calliditas Therapeutics

Calliditas Therapeutics R&D Day, 2024

Videopræsentation30.5.2024, 13.00

Calliditas Therapeutics R&D Day, 2024

Calliditas Therapeutics

Pressemeddelelse28.5.2024, 12.00

Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress

Calliditas Therapeutics

Selskabsmeddelelse28.5.2024, 06.30

Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation

Calliditas Therapeutics

Pressemeddelelse24.5.2024, 05.11

Redeye: Calliditas Q1 - Powerful launch momentum

Calliditas Therapeutics

Calliditas Therapeutics, Audiocast with teleconference, Q1'24

Videopræsentation23.5.2024, 12.30

Calliditas Therapeutics, Audiocast with teleconference, Q1'24

Calliditas Therapeutics

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.